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The Third World Symposium on Pulmonary Arterial Hypertension served not only as a
forum for the presentation of state-of-the art overviews of the pathobiologic and clinical
aspects of pulmonary arterial hypertension (PAH), but also afforded an opportunity to the
international scientific community to explore future directions of research and collaboration.
This summary provides a brief overview of future directions in the field. (J Am Coll Cardiol
2004;43:89S–90S) © 2004 by the American College of Cardiology Foundationh
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wdentification of mutations in the bone morphogenetic
rotein receptor-2 (BMPR2) in the majority of cases of
amilial pulmonary arterial hypertension (FPAH) has been a
ajor advance in the elucidation of the pathogenic sequence
n pulmonary arterial hypertension (PAH) (1,2). However,
ewer than 20% of individuals with a BMPR2 mutation
evelop FPAH, and most individuals who develop PAH do
ot have an identifiable mutation (3); accordingly, it is likely
hat other factors, including genes and environmental stim-
li, are needed to initiate the pathological sequence that
eads to vascular injury and the pulmonary hypertensive
tate. Both the role of these other factors in initiating the
asculopathic process and the mechanisms through which
hey interface with genetic abnormalities are unknown (4).
Various cellular pathway abnormalities have been de-
cribed that may play important roles in the development
nd progression of PAH (5–9). These include altered
ynthesis of nitric oxide, prostacyclin and endothelin, im-
aired potassium channel and growth factor receptor func-
ion, altered serotonin transporter regulation, increased
xidant stress, and enhanced matrix production. However,
he relative importance of each of these processes is un-
nown, and the interactions between these various pathways
hould be explored. Additionally, the intermediate steps
nvolved in the transduction of signals related to BMPR2
re unknown; clarification of these pathways will lead to a
ore complete understanding of how impaired BMPR2
ignaling leads to hypertensive pulmonary vascular disease
10,11).
HERAPY OF PAH
ess than a decade ago, the treatment of PAH was based on
limited understanding of the disease pathogenesis and was
argely empiric and usually ineffective. The treatment of
AH has advanced dramatically since then, with a number
ell-designed clinical trials demonstrating efficacy of several
herapies that target specific abnormalities present in PAH
12–15). Furthermore, the complexity of these treatments
From the *Pulmonary Vascular Center, University of California–San Diego School
f Medicine, La Jolla, California; and the †Institute of Cardiology, University of
ologna, Bologna, Italy.gManuscript received January 29, 2004; accepted February 3, 2004.as devolved from continuous intravenous (IV) delivery to
ral and inhaled modes of drug delivery. Despite these
uccesses, the response to therapy of PAH is not universal
nd is often incomplete. Future studies targeting newly
dentified alterations in endothelial and smooth muscle cell
unction, including phosphodiesterase-5 (PDE5) and an-
iotensin activity, vasoactive intestinal peptide synthesis and
ctivity (16), and the serotonin pathway (9,17) may provide
ovel treatments.
Drugs currently marketed to treat other conditions may
ave effects that are beneficial in PAH as well. For example,
he hydroxymethylglutaryl-coenzyme-A reductase inhibi-
ors manifest pleiotropic effects that have been suggested to
e responsible for a component of their benefit in arterio-
clerotic disease (18), and these agents attenuate the pul-
onary arteriopathy induced by the administration of
onocrotaline to experimental animals (19,20). Formal
linical studies with the statins may, therefore, be appropri-
te. Similarly, currently available platelet inhibitors (i.e.,
spirin) and newer antithrombotic agents may have a role in
he treatment of PAH, in light of the beneficial effects (and
nherent risks) of anticoagulation with warfarin in idio-
athic PAH.
As with other diseases with a complex pathogenesis,
argeting a single pathway in PAH is unlikely to be
niformly successful. With the development of several
athway-specific therapies, the opportunity exists for eval-
ating multidrug therapy in PAH: for example, studies
ombining an endothelin receptor antagonist with a prosta-
oid or a PDE5 inhibitor may lead to either a more
ggressive first-line treatment strategy combining several
rugs, or to a strategy of layered therapy for disease
rogression, or both.
EASURING OUTCOMES AND
ONITORING THE COURSE OF THERAPY
he development of treatments for PAH has prompted the
hallenge of how to best assess and monitor the efficacy of
ong-term therapy. Because it is believed that randomized,
lacebo-controlled trials using survival as an end point
ould be unethical to perform in PAH, alternative strate-
ies are required to measure and compare the relative effects
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Future Directions in PAH June 18, 2004:89S–90Sf the available treatments. Similarly, noninvasive markers
f disease severity, either biomarkers or physiological tests,
re needed that can be widely applied to reliably monitor
linical course. Studies that assess the value of these out-
ome measures, alone or in combination, will enable phy-
icians to time and select therapy in a more structured
ashion.
onclusions. Although major advances in our understand-
ng of the mechanism of disease development and in the
reatment of PAH have been achieved over the past decade,
ubstantial gaps in our knowledge remain. Bringing to-
ether physicians and scientists representing multiple disci-
lines and expertise, all sharing an interest in PAH, afforded
he opportunity to explore areas of mutual interest and
ollaboration that will, it is hoped, narrow these gaps of
nowledge in the future. Ultimately, the success of the
hird World Symposium on Pulmonary Arterial Hyperten-
ion will be best measured by the progress achieved in
nderstanding and treating PAH over the next few years.
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